Cargando…
Novel Experimental and Clinical Therapeutic Uses of Low-Molecular-Weight Heparin/Protamine Microparticles
Low-molecular-weight heparin/protamine microparticles (LMW-H/P MPs) were produced as a carrier for heparin-binding growth factors (GFs) and for various adhesive cells. A mixture of low-molecular-weight heparin (MW: approximately 5000 Da, 6.4 mg/mL) and protamine (MW: approximately 3000 Da, 10 mg/mL)...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834902/ https://www.ncbi.nlm.nih.gov/pubmed/24300179 http://dx.doi.org/10.3390/pharmaceutics4010042 |
_version_ | 1782292062971887616 |
---|---|
author | Kishimoto, Satoko Ishihara, Masayuki Takikawa, Megumi Mori, Yasutaka Hattori, Hidemi Fujita, Masanori Nakamura, Shingo |
author_facet | Kishimoto, Satoko Ishihara, Masayuki Takikawa, Megumi Mori, Yasutaka Hattori, Hidemi Fujita, Masanori Nakamura, Shingo |
author_sort | Kishimoto, Satoko |
collection | PubMed |
description | Low-molecular-weight heparin/protamine microparticles (LMW-H/P MPs) were produced as a carrier for heparin-binding growth factors (GFs) and for various adhesive cells. A mixture of low-molecular-weight heparin (MW: approximately 5000 Da, 6.4 mg/mL) and protamine (MW: approximately 3000 Da, 10 mg/mL) at a ratio of 7:3 (vol:vol) yields a dispersion of microparticles (0.5–3 µm in diameter). LMW-H/P MPs immobilize, control the release and protect the activity of GFs. LMW-H/P MPs can also bind to cell surfaces, causing these cells to interact with the LMW-H/P MPs, inducing cells/MPs-aggregate formation and substantially promoting cellular viability. Furthermore, LMW-H/P MPs can efficiently bind to tissue culture plates and retain the binding of important GFs, such as fibroblast growth factor (FGF)-2. The LMW-H/P MPs-coated matrix with various GFs or cytokines may provide novel biomaterials that can control cellular activity such as growth and differentiation. Thus, LMW-H/P MPs are an excellent carrier for GFs and various cells and are an efficient coating matrix for cell cultures. |
format | Online Article Text |
id | pubmed-3834902 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-38349022013-11-21 Novel Experimental and Clinical Therapeutic Uses of Low-Molecular-Weight Heparin/Protamine Microparticles Kishimoto, Satoko Ishihara, Masayuki Takikawa, Megumi Mori, Yasutaka Hattori, Hidemi Fujita, Masanori Nakamura, Shingo Pharmaceutics Review Low-molecular-weight heparin/protamine microparticles (LMW-H/P MPs) were produced as a carrier for heparin-binding growth factors (GFs) and for various adhesive cells. A mixture of low-molecular-weight heparin (MW: approximately 5000 Da, 6.4 mg/mL) and protamine (MW: approximately 3000 Da, 10 mg/mL) at a ratio of 7:3 (vol:vol) yields a dispersion of microparticles (0.5–3 µm in diameter). LMW-H/P MPs immobilize, control the release and protect the activity of GFs. LMW-H/P MPs can also bind to cell surfaces, causing these cells to interact with the LMW-H/P MPs, inducing cells/MPs-aggregate formation and substantially promoting cellular viability. Furthermore, LMW-H/P MPs can efficiently bind to tissue culture plates and retain the binding of important GFs, such as fibroblast growth factor (FGF)-2. The LMW-H/P MPs-coated matrix with various GFs or cytokines may provide novel biomaterials that can control cellular activity such as growth and differentiation. Thus, LMW-H/P MPs are an excellent carrier for GFs and various cells and are an efficient coating matrix for cell cultures. MDPI 2012-01-11 /pmc/articles/PMC3834902/ /pubmed/24300179 http://dx.doi.org/10.3390/pharmaceutics4010042 Text en © 2012 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Kishimoto, Satoko Ishihara, Masayuki Takikawa, Megumi Mori, Yasutaka Hattori, Hidemi Fujita, Masanori Nakamura, Shingo Novel Experimental and Clinical Therapeutic Uses of Low-Molecular-Weight Heparin/Protamine Microparticles |
title | Novel Experimental and Clinical Therapeutic Uses of Low-Molecular-Weight Heparin/Protamine Microparticles |
title_full | Novel Experimental and Clinical Therapeutic Uses of Low-Molecular-Weight Heparin/Protamine Microparticles |
title_fullStr | Novel Experimental and Clinical Therapeutic Uses of Low-Molecular-Weight Heparin/Protamine Microparticles |
title_full_unstemmed | Novel Experimental and Clinical Therapeutic Uses of Low-Molecular-Weight Heparin/Protamine Microparticles |
title_short | Novel Experimental and Clinical Therapeutic Uses of Low-Molecular-Weight Heparin/Protamine Microparticles |
title_sort | novel experimental and clinical therapeutic uses of low-molecular-weight heparin/protamine microparticles |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834902/ https://www.ncbi.nlm.nih.gov/pubmed/24300179 http://dx.doi.org/10.3390/pharmaceutics4010042 |
work_keys_str_mv | AT kishimotosatoko novelexperimentalandclinicaltherapeuticusesoflowmolecularweightheparinprotaminemicroparticles AT ishiharamasayuki novelexperimentalandclinicaltherapeuticusesoflowmolecularweightheparinprotaminemicroparticles AT takikawamegumi novelexperimentalandclinicaltherapeuticusesoflowmolecularweightheparinprotaminemicroparticles AT moriyasutaka novelexperimentalandclinicaltherapeuticusesoflowmolecularweightheparinprotaminemicroparticles AT hattorihidemi novelexperimentalandclinicaltherapeuticusesoflowmolecularweightheparinprotaminemicroparticles AT fujitamasanori novelexperimentalandclinicaltherapeuticusesoflowmolecularweightheparinprotaminemicroparticles AT nakamurashingo novelexperimentalandclinicaltherapeuticusesoflowmolecularweightheparinprotaminemicroparticles |